Malaghan Institute To Conduct New Zealand’s First CAR T-Cell Therapy Clinical Trial for Refractory non-Hodgkin Lymphoma Patients

Malaghan Institute To Conduct New Zealand’s First CAR T-Cell Therapy Clinical Trial for Refractory non-Hodgkin Lymphoma Patients

The Malaghan Institute of New Zealand will commence a Phase I clinical trial of a CAR T-cell therapy treatment, the first in New Zealand, in a bid to redirect patients’ immune systems to build protection against cancer. The study will involve up to 12 participants...

Pin It on Pinterest